Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Sasithon Pukrittayakamee

Professor Sasithon Pukrittayakamee

Research groups

Sasithon Pukrittayakamee

Consultant Physician

  • co-Head of CTU

Professor Sasithon Pukrittayakamee is an honorable consultant in the Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University in Bangkok. Professor Sasithon is a member of MORU and co-Head along with Professor Sir Nick White of MORU’s Clinical Therapeutics Unit (CTU).

Prof. Sasithon is an internationally recognized malariologist. She has been a key research Mahidol-Oxford collaborator for over 30 years and has led important research on the pathophysiology and treatment of malaria. She continues to lead an active research team who conduct pharmacological studies of antimalarial and ant-influenza drugs, in addition to clinical research on malaria in Thailand.

A Fellow of the Royal Society, Thailand since 2018, Prof. Sasithon earned her D.Phil (Oxon) St. Cross College, University of Oxford, U.K. in 1985 as part of a Wellcome Trust Scholarship on clinical immunology at Oxford’s John Radcliffe Hospital.

Prof. Sasithon’s many professional memberships include the editorial board of the International Journal of the Royal Society of Thailand, Scientific Research committee of Mahidol University, Committee member of Ethical committee at Faculty of Tropical Medicine, member of the Parasitology and Tropical Medicine Association of Thailand, Medicine Dictionary Committee (English-Thai) at the Royal Society, Thailand, members of the Thai Medical Council and St. Cross College, University of Oxford.

She has published over 200 articles and her current and future focuses are on radical cure of vivax malaria in G6PD deficiency people, optimized uses of malaria vaccine, fight against artemisinin resistance and future triple artemisinin combination therapies.